Kumar K M, Anitha P, Sivasakthi V, Bag Susmita, Lavanya P, Anbarasu Anand, Ramaiah Sudha
School of Biosciences and Technology, VIT University, Vellore, 632014, Tamil Nadu, India.
3 Biotech. 2014 Jun;4(3):241-251. doi: 10.1007/s13205-013-0147-z. Epub 2013 Jun 11.
Upper respiratory tract infection (URTI) is an acute infection which involves the upper respiratory tract: nose, sinuses, tonsils and pharynx. URT infections are caused mainly by pathogenic bacteria like Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus. Conventionally, β-lactam antibiotics are used to treat URT infections. Penicillin binding proteins (PBPs) catalyze the cell wall synthesis in bacteria. β-Lactam antibiotics like Penicillin, Cephalosporins, Carbapenems and Monobactams inhibit bacterial cell wall synthesis by binding with PBPs. Pathogenic bacteria have efficiently evolved to resist these β-lactam antibiotics. New generation antibiotics are capable of inhibiting the action of PBP due to its new and peculiar structure. New generation antibiotics and Penicillin derivatives are selected in this study and virtually compared on the basis of interaction studies. 3-Dimensional (3D) interaction studies between Lactivicin, Cefuroxime, Cefadroxil, Ceftaroline, Ceftobiprole and Penicillin derivatives with PBPs of the above-mentioned bacteria are carried out. The aim of this study was to suggest a potent new generation molecule for further modification to increase the efficacy of the drug for the URTI.
上呼吸道感染（URTI）是一种涉及上呼吸道（鼻子、鼻窦、扁桃体和咽部）的急性感染。URT感染主要由肺炎链球菌、流感嗜血杆菌和金黄色葡萄球菌等病原菌引起。传统上，β-内酰胺类抗生素用于治疗URT感染。青霉素结合蛋白（PBPs）催化细菌细胞壁的合成。青霉素、头孢菌素、碳青霉烯类和单环β-内酰胺类等β-内酰胺类抗生素通过与PBPs结合来抑制细菌细胞壁的合成。病原菌已经有效地进化以抵抗这些β-内酰胺类抗生素。新一代抗生素由于其新颖独特的结构能够抑制PBP的作用。本研究选择了新一代抗生素和青霉素衍生物，并基于相互作用研究进行了虚拟比较。开展了拉克替丁、头孢呋辛、头孢羟氨苄、头孢洛林、头孢托罗与上述细菌的PBPs之间的三维（3D）相互作用研究。本研究的目的是提出一种有效的新一代分子，以便进一步修饰，提高该药物对上呼吸道感染的疗效。
